The Traderszone Network

Published in TZ Latest News 29 February, 2016 by The TZ Newswire Staff

Why Cara Therapeutics Plunged 37% Last Week (CARA)

Biopharma stocks live and breathe with successful drug trials, making them risky investments since their performance often hinge on FDA decisions.